Want to see HK:6998 full AI Analyst Report?
Top Page
Genor Biopharma Holdings Limited
(6998)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$2.00
▼(-34.64% Downside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by improved 2025 fundamentals (profitability and positive free cash flow) but tempered by historical volatility and the sharp increase in debt. Technically, the stock is in a clear downtrend (below major moving averages with negative MACD), despite oversold readings. Valuation is a supportive factor given the very low P/E.
Positive Factors
2025 revenue and margin turnaround
A large, profitable revenue step-up in 2025 indicates the company can scale commercialized biologics and capture market demand. Sustained mid-to-high double-digit EBIT margins provide room to fund R&D, manufacturing scale-up and commercialization without relying solely on external capital.
Negative Factors
Historical revenue and profit volatility
The 2025 earnings step-change follows years of inconsistent revenue and losses, including periods with zero reported sales. This weak track record raises execution risk: sustaining revenue growth and margins across product launches and competition remains unproven over a full cycle.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 revenue and margin turnaround
A large, profitable revenue step-up in 2025 indicates the company can scale commercialized biologics and capture market demand. Sustained mid-to-high double-digit EBIT margins provide room to fund R&D, manufacturing scale-up and commercialization without relying solely on external capital.
Read all positive factors
Genor Biopharma Holdings Limited (6998) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.78B
Dividend YieldN/A
Average Volume (3M)909.38K
Price to Earnings (P/E)6.9
Beta (1Y)0.48
Revenue Growth1117.02%
EPS GrowthN/A
CountryHK
Employees1,545
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,014,041,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.17
Price to Sales (P/S)1.67
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genor Biopharma Holdings Limited Business Overview & Revenue Model
Company Description
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally....
How the Company Makes Money
null...
Genor Biopharma Holdings Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
63
Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.70B | 2.76B | 0.00 | 18.53M | 0.00 |
| Gross Profit | 1.76B | 1.78B | -84.96M | -45.04M | -73.21M |
| EBITDA | 954.29M | 924.14M | -686.81M | -851.84M | -1.03B |
| Net Income | 433.01M | 420.56M | -745.17M | -849.15M | -1.04B |
Balance Sheet | |||||
| Total Assets | 6.61B | 1.29B | 1.45B | 2.12B | 2.86B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.06B | 1.17B | 1.59B | 2.20B |
| Total Debt | 1.49B | 911.00K | 7.16M | 28.59M | 57.41M |
| Total Liabilities | 2.75B | 138.05M | 256.18M | 309.87M | 369.73M |
| Stockholders Equity | 3.86B | 1.15B | 1.19B | 1.80B | 2.49B |
Cash Flow | |||||
| Free Cash Flow | 404.05M | -123.55M | -426.15M | -590.56M | -695.13M |
| Operating Cash Flow | 451.73M | -121.98M | -425.12M | -577.61M | -623.74M |
| Investing Cash Flow | 1.24B | 8.01M | 5.99M | -12.94M | -54.26M |
| Financing Cash Flow | -744.78M | -1.56M | -6.82M | -57.39M | 17.57M |
Genor Biopharma Holdings Limited Technical Analysis
Negative
3.06
Price Trends
2.00
Negative
2.46
Negative
2.83
Negative
Market Momentum
>-0.01
Negative
49.11
Neutral
67.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6998, the sentiment is Negative. The current price of 3.06 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 2.00, and above the 200-day MA of 2.83, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.11 is Neutral, neither overbought nor oversold. The STOCH value of 67.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6998.
Genor Biopharma Holdings Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.78B | 6.90 | 2.04% | ― | 1117.02% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | HK$1.67B | 25.77 | 43.89% | ― | 150.60% | ― | |
48 Neutral | HK$2.59B | -9.32 | -26.73% | ― | 14.59% | 22.41% | |
45 Neutral | HK$3.66B | -21.61 | -17.64% | ― | -65.87% | 6.71% | |
43 Neutral | HK$1.54B | -11.40 | -27.70% | ― | -100.00% | 50.29% | |
43 Neutral | HK$2.91B | -5.65 | -32.79% | ― | 109.02% | 36.95% |
* General Sector Average
HK:6998
Genor Biopharma Holdings Limited
1.88
-0.80
-29.85%
HK:6996
Antengene Corporation Limited
4.09
-0.29
-6.62%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.65
-2.46
-34.60%
HK:2181
Mabpharm Limited
0.41
-0.07
-15.62%
HK:3681
SinoMab Bioscience Ltd.
1.12
-1.33
-54.29%
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
3.46
-7.66
-68.88%
Genor Biopharma Holdings Limited Corporate Events
Edding Genor Realises US$48.4 Million from Sale of Candid Stake After UCB Takeover
Jul 16, 2026
Edding Genor Group Holdings has disclosed the disposal of its entire 2.29% equity stake in Candid Therapeutics following Candid’s acquisition by Belgian drugmaker UCB, receiving US$48.4 million as part of the cash consideration. The transact...
Edding Genor Launches Up to 10% Share Buyback Ahead of 2027 AGM
Jul 7, 2026
Edding Genor Group Holdings Limited has announced that its board will exercise a shareholder-approved mandate to repurchase up to 10% of the company’s issued shares on the open market before the 2027 annual general meeting. The repurchased s...
Edding Genor Wins NMPA Nod for Phase Ib/II Trial of Trispecific Breast Cancer Antibody GB268
Jul 2, 2026
Edding Genor Group Holdings Limited has secured approval from China’s National Medical Products Administration for an Investigational New Drug application to conduct a Phase Ib/II clinical trial of GB268 in locally advanced unresectable or m...
Edding Genor shareholders back board, accounts and 10% buyback mandate at AGM
Jun 26, 2026
Edding Genor Group Holdings Limited reported that all resolutions at its 26 June 2026 annual general meeting in Shanghai were approved by poll, with 1,990,748,274 shares eligible to vote after excluding treasury stock. The meeting, chaired by chai...
Edding Genor Chair to Boost Shareholding in USD1 Million Plan
Jun 10, 2026
Edding Genor Group Holdings Limited has announced that its chairman, executive director and chief executive officer, Ni Xin, plans to increase his stake in the company through open-market share purchases funded with his personal capital. The plann...
Edding Genor Reshapes Company Secretariat as Hong Kong Grants Governance Waiver
May 13, 2026
Edding Genor Group Holdings announced that joint company secretary Zhai Jing will resign effective 13 May 2026 to focus on business development, with the board noting she has no disagreements and no issues requiring shareholder attention. The move...
Edding Genor’s GB261 Gains Momentum as UCB Moves to Acquire Licensee Candid Therapeutics
May 4, 2026
Edding Genor has been advancing GB261 through a global licensing strategy, having granted Candid Therapeutics exclusive rights outside Greater China to develop and commercialize the bispecific antibody. The deal structure combines equity participa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.